Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/1999
08/11/1999EP0934273A1 New derivates from piperidine-keto acid, their preparation and use
08/11/1999EP0934270A1 A method of treating cancer
08/11/1999EP0934267A1 $g(a)-AMINO SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS
08/11/1999EP0934259A1 Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors
08/11/1999EP0934249A1 Conformationally restricted polyamines and their use as antineoplastic agents
08/11/1999EP0934081A2 Antineoplastic conjugates of transferrin, albumin and polyethylene glycol
08/11/1999EP0934065A1 Pharmaceutical compounds
08/11/1999EP0789706A4 Sugar modified nucleosides and their use for synthesis of oligonucleotides
08/11/1999EP0759032B1 Isolated, mage-3 derived peptides which complex with hla-a2 molecules and uses thereof
08/11/1999EP0741744B1 Immunogens against gonadotropin releasing hormone
08/11/1999EP0646132B1 Amino sugars, glycoproteins, method of preparing them, medicines containing them and their use
08/11/1999EP0642509B1 Novel potent inducers of terminal differentiation and methods of use thereof
08/11/1999EP0566666B1 Novel glucohydrolase inhibitors useful as antidiabetic antivital and antimetastatic agents
08/11/1999EP0478545B1 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
08/11/1999CN1225682A Method and compositions for regulating T cell subsets by modulating transcription facter activity
08/11/1999CN1225654A Angiogenic inhibitory compounds
08/11/1999CN1225639A Phosphinate based inhibitors of matrix metalloproteases
08/11/1999CN1225637A Pyrrole triazines and pyrimidines
08/11/1999CN1225623A Inhibition of matrix metalloproteases by acetylene contg. compounds
08/11/1999CN1225622A Substituted oxobutyric acids as matrix metalloprotease inhibitor
08/11/1999CN1225621A Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
08/11/1999CN1225620A Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors
08/11/1999CN1225590A Peptides with increased binding affinity for HLA molecules
08/11/1999CN1225368A Interleukin -2/granulocyte-macrophage colony stimulating factor fusion protein
08/11/1999CN1225367A Bond partner, and use for sieving inhibitor and diagnosis and treatment of disease
08/11/1999CN1225360A Substituted imidazolidine derivatives, their prepn., their use and pharmaceutical prepn. comprising them
08/11/1999CN1225279A Radioactive rhenium marking tin-sulphur colloid agent, prepn. method and use therefor
08/10/1999US5936123 Compounds such as 3-isopropyl-4-hydrazinobenzoic acid and its salts
08/10/1999US5936097 Antitumor agents
08/10/1999US5936084 Halo-substituted bisindolemaleimide protein kinase C inhibitors
08/10/1999US5936067 Macrophage inflammatory protein variants
08/10/1999US5935998 Use of all allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection or associated diseases
08/10/1999US5935995 Poly-, oligo- and monosaccharides of drugs, e.g. nitrogen mustard gas, quinine and dipyridamole; stability; slow release; antiarthitic agents; enzyme inhibitors
08/10/1999US5935962 Administering doxazosin, a metabolite or a salt
08/10/1999US5935955 Substituted 3,6-dibenzylidene-2,5-piperazinediones, modulators of multidrug resistance
08/10/1999US5935954 Compounds with improved multi-drug resistance activity
08/10/1999US5935931 Human apoptosis-related calcium-binding protein
08/10/1999US5935928 Modified platelet factor-4
08/10/1999US5935865 Semaphorin gene family
08/10/1999US5935860 Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
08/10/1999US5935835 The invention relates to novel polynucleotides and polypeptides of the family of cdc-regulatory kinases, hereinafter referred to as human myt-1 kinase.
08/10/1999US5935830 Site-directed mutagenesis by forming triple helix with double-stranded dna and oligonucleotide with electrophilic group, electrophilic group causes modification of dna nucleotide, then replication causes mutation
08/10/1999US5935821 Nucleotide sequence that codes polypeptide anti-idiotype immunoglobulin a ganglioside useful in the suppression of cancer and reduction of recurrence; anticarcinogenic agents
08/10/1999US5935820 Polynucleotides encoding vascular endothelial growth factor 2
08/10/1999US5935817 Genetic engineering
08/10/1999US5935814 G-protein coupled receptor family polypeptides, referred to as hfgan72y, altered nucleic acid seqences encoding it and recombinant materials and methods for its production; use in design of protocols and treatment of various infections
08/10/1999US5935812 Polynucleotide
08/10/1999US5935602 Dosage forms of risedronate
08/10/1999US5935585 Novel compounds useful in topical and systemic treatment of dermatological conditions associated with a keratinization disorder, and inflammatory or immunoallergenic component; body and hair care cosmetics
08/10/1999US5935569 Genetic anticancer vaccine
08/10/1999US5935568 Gene therapy for effector cell regulation
08/10/1999US5935567 Administering a polypeptide ip-10, or a suitable dna vector encoding the polypeptide ip-10
08/10/1999US5935565 Method for increasing the level of stem cells in peripheral blood
08/10/1999CA2098593C Treatment method for cancer
08/10/1999CA2004695C Phospholipid nucleosides
08/10/1999CA1340704C Human interferon-gamma, process to prepare said human interferon-gamma, and its use
08/09/1999CA2245999A1 Novel compounds
08/05/1999WO1999038998A1 Methods of identifying modulators of kinases responsive to stress
08/05/1999WO1999038983A1 Novel sphingosine-1 phosphate lyase
08/05/1999WO1999038973A2 Compounds for therapy and diagnosis of lung cancer and methods for their use
08/05/1999WO1999038969A1 PROTEIN HUMAINE β-TrCP
08/05/1999WO1999038964A2 Promoter regions of the mouse and human telomerase rna component genes
08/05/1999WO1999038963A1 Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
08/05/1999WO1999038954A1 A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
08/05/1999WO1999038870A1 Compounds containing boron for electron microscopy and for boron neutron-capture therapy
08/05/1999WO1999038862A1 Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof
08/05/1999WO1999038850A1 Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
08/05/1999WO1999038843A1 Hydroxamic and carboxylic acid derivatives
08/05/1999WO1999038528A2 Vaccine formulations
08/05/1999WO1999038525A1 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
08/05/1999WO1999028493A3 Method for identifying inhibitors of g-protein coupled receptor hibef51
08/05/1999WO1999025843A3 Human checkpoint kinase, hcds1, compositions and methods
08/05/1999WO1999025367A3 Treatment of hematologic disorders
08/05/1999WO1999024559A3 Nuclear targeting by means of streptococcal protein h
08/05/1999WO1999023216A3 Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
08/05/1999WO1999022722A3 Use of macrolides for the treatment of cancer and macular degeneration
08/05/1999WO1999020121A9 Methods for obtaining protein mixtures and control factors from wound granulation, epithelialization or determined blastocyst tissue
08/05/1999WO1999019359A8 Cellular receptor for hiv-1 vpr essential for g2/m phase transition of the cell cycle
08/05/1999WO1999018210A3 Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
08/05/1999WO1999014226A3 Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
08/05/1999DE19804251A1 Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament Biphenylsulfonylcyanamide, processes for their preparation and their use as a medicament
08/05/1999CA2319711A1 Vaccine
08/05/1999CA2319710A1 Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
08/05/1999CA2319698A1 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
08/05/1999CA2319117A1 Compounds for therapy and diagnosis of lung cancer and methods for their use
08/05/1999CA2317459A1 Methods of identifying modulators of kinases responsive to stress
08/04/1999EP0933351A1 Tricyclic retinoids, methods for their production and use
08/04/1999EP0933350A1 Tricyclic retinoids, methods for their production and use
08/04/1999EP0932686A2 Telomerase reverse transcriptase
08/04/1999EP0932683A1 Attenuated microorganism strains expressing hpv proteins
08/04/1999EP0932679A1 METHODS AND COMPOSITIONS FOR DELIVERY AND EXPRESSION OF INTERFERON-$g(a) NUCLEIC ACIDS
08/04/1999EP0932678A2 A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
08/04/1999EP0932668A1 Two human cathepsin proteins
08/04/1999EP0932626A1 G protein-coupled receptor antagonists
08/04/1999EP0932606A1 Inhibitors of prenyl transferases
08/04/1999EP0932420A1 Drug delivery using terminal complement components
08/04/1999EP0932417A1 Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
08/04/1999EP0932411A1 Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
08/04/1999EP0932410A1 Mistletoe (viscum) extracts
08/04/1999EP0932402A1 Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
1 ... 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 ... 2211